Ocular Allergy

Investigators zoom in on future of dry eye treatment

Autologous serum eye drops and blood products offer hope to patients.

The sky is the limit for allergy pipeline

Growing patient pool is driving clinical trial investment.

Study: Sore eyes a common symptom in COVID-19 patients

Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.

Applying hydrogel technology to sustained-release ocular drugs

October 15, 2017

Hydrogel technology enables the use of drugs that are known to be efficacious for ocular diseases and conditions when formulated as daily drops or monthly injections, into one-time or several-month dosage forms.

New therapies needed for allergy symptoms, quality of life

October 08, 2017

Half of patients with ocular allergies report experiencing symptoms year-round. While nearly all of them take eye drops to treat their symptoms, the majority report limited or no effect from over-the-counter drops, according to a new survey. The results suggest that new treatment approaches would improve both symptoms and quality of life.

Topical cetirizine latest therapy to treat allergic conjunctivitis

August 04, 2017

Oral cetirizine is one of the most used oral medications for treatment of allergic rhinitis. In May 2017, the FDA approved the first ophthalmic formulation of the second-generation histamine-1 (H1) receptor antagonist for use in treating ocular itching associated with allergic conjunctivitis.

The latest ocular allergy treatments worth watching

July 02, 2017

Progress of ocular allergy treatment in 2017 starts with the fact that this is a mature therapeutic space, with a range of existing choices for clinicians and patients. Progression in therapies from artificial tears to antihistamines and mast cell stabilizers to topical steroids provides a suitable choice for most patients with ocular allergies.

Intracanalicular insert soothes ocular itching in allergic conjunctivitis

June 16, 2017

A phase III study of dexamethasone insert, 0.4 mg (Dextenza, Ocular Therapeutix) found that the sustained-release intracanalicular insert is safe, effective, and well tolerated for treating ocular itching associated with allergic conjunctivitis.